Edition:
United Kingdom

Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

67.74EUR
9:51am BST
Change (% chg)

€0.32 (+0.47%)
Prev Close
€67.42
Open
€67.54
Day's High
€67.98
Day's Low
€67.48
Volume
141,098
Avg. Vol
1,300,743
52-wk High
€72.76
52-wk Low
€58.96

Select another date:

Mon, Oct 1 2018

Delaware judge says Fresenius can walk away from $4.8 billion Akorn deal

WILMINGTON, Del Germany's Fresenius SE won a rare court ruling allowing the healthcare group to walk away from its $4.75 billion takeover of Akorn Inc , sparking a more than 50 percent fall in the U.S. generic drugmaker's shares.

Delaware judge says Fresenius can walk away from $4.8 billion Akorn deal

WILMINGTON, Del Germany's Fresenius SE won a rare court ruling allowing the healthcare group to walk away from its $4.75 billion takeover of Akorn Inc , sparking a more than 50 percent fall in the U.S. generic drugmaker's shares.

REFILE-UPDATE 2-Delaware judge says Fresenius can walk away from $4.8 bln Akorn deal

WILMINGTON, Del, Oct 1 Germany's Fresenius SE won a rare court ruling allowing the healthcare group to walk away from its $4.75 billion takeover of Akorn Inc , sparking a more than 50 percent fall in the U.S. generic drugmaker's shares.

Judge rules for Fresenius in bid to end $4.8 bln Akorn deal

WILMINGTON, Del, Oct 1 A Delaware judge ruled on Monday that German healthcare group Fresenius SE could walk away from its $4.75 billion deal for U.S. drugmaker Akorn Inc and rejected Akorn's claim that the merger agreement had been breached.

Fresenius shares jump on report of win in Akorn ruling

LONDON Shares in German healthcare group Fresenius surged up 9.3 percent on Monday after a Bloomberg report that the firm won a ruling to pull out of a $4.3 billion deal to buy U.S. generic pharmaceuticals company Akorn .

UPDATE 3-Akorn row overshadows Fresenius' generics guidance

* CEO says expect case to be resolved by early 2019 (Adds CEO comments from analyst call)

Fresenius nudges up Kabi earnings guidance

BERLIN, July 31 Fresenius SE nudged up its earnings guidance for its Kabi generics unit on Tuesday as it posted a 3 percent rise in adjusted group net profit in the second quarter.

Fresenius transfers inpatient rehabilitation business to Vamed unit

FRANKFURT, June 6 German healthcare group Fresenius said it was transferring its inpatient rehabilitation business from its private hospital operations to its Fresenius Vamed unit to better enable continued growth at the two businesses.

Fresenius CEO defends canceled Akorn deal

FRANKFURT/BERLIN Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn , saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

Fresenius CEO defends cancelled Akorn deal

FRANKFURT/BERLIN Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion (3.6 billion pounds) takeover of Akorn , saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

Select another date: